PMEF
KLRS

Point72 Middle East FZE’s Kalaris Therapeutics KLRS Stock Holding History

Point72 Middle East FZE’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-354
Closed -$27.7K – 1961
2023
Q2 		$27.7K Buy
354
+281
+385% +$26.7K ﹤0.01% 1354
2023
Q1 		$6.63K Sell
73
-144
-66% -$18.3K ﹤0.01% 1505
2022
Q4 		$25.6K Buy
+217
New +$36.8K ﹤0.01% 1589

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Middle East FZE's KLRS Position: Q3 2023 in Review

Point72 Middle East FZE sold out of Kalaris Therapeutics (KLRS) in Q3 2023, closing a stake of 354 shares — an estimated $27.7K sold.

Point72 Middle East FZE first reported a position in KLRS in Q4 2022 and held it in 3 quarters. The position peaked at $27.7K in Q2 2023. 90 funds tracked by Wall St. Rank hold KLRS as of Q3 2023.

  • Point72 Middle East FZE reported no remaining Kalaris Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 354 Kalaris Therapeutics shares in Q3 2023, an estimated $27.7K.
  • Point72 Middle East FZE first reported a position in Kalaris Therapeutics in Q4 2022 and held it in 3 quarters.
  • Point72 Middle East FZE's Kalaris Therapeutics position peaked at $27.7K in Q2 2023.
  • 90 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2023.

Based on Point72 Middle East FZE's 13F filing for Q3 2023, filed 14 Nov 2023.